Low fasting plasma insulin is associated with atrial fibrillation in men from a cohort study - the Malmö preventive project

BMC Cardiovascular Disorders

Peter M Nilsson¹  Gunnar Engström¹  Tord Juhlin¹  Linda SB Johnson¹ 

[1] Department of Clinical Sciences, Lund University, Skåne University Hospital, Inga-Marie Nilssons väg 49, 20502 Malmö, Sweden

关键词: Population;    Hypertension;    Fasting plasma insulin;    Atrial fibrillation;   

Others  :  1088465
DOI  :  10.1186/1471-2261-14-107

 received in 2014-01-08, accepted in 2014-08-20,  发布年份 2014

【 摘 要 】

Background

Type 2 diabetes has been associated with increased incidence of atrial fibrillation (AF) and cardiovascular disease. Controversy remains regarding the role of insulin in the epidemiology of AF risk. The aim of the present study was to study the association between fasting plasma insulin (FPI) and incidence of AF, as well as any effect modification by fasting blood glucose (FBG) or 2 h post-load blood glucose and body mass index (BMI).

Methods

The study population consisted of 6052 men and 1014 women followed for an average of 26.2 years. There were 983 cases of incident AF. Analysis was performed using Cox regression and competing risks regression approaches. The population was analysed as a whole, and by subgroups according to glucose levels and BMI.

Results

After adjustment for age, height, weight, systolic blood pressure and smoking there was a significant inverse association between FPI and AF (hazard ratio; HR) for 4th vs. 1st quartile: 0.69 (95% confidence interval (CI): 0.57-0.83, p < 0.0001) in the cohort as a whole. Among men the corresponding values were HR 0.64 (95% CI 0.52-0.78, p < 0.001) and among women HR 1.16 (95% CI 0.69-1.93, p = 0.58); p-value for interaction 0.06. The protective effects of insulin tended to be weaker in subjects with elevated fasting glucose, implying that the relation between FPI and incident AF could be dependent on the status of individual’s glucose metabolism.

Conclusions

High levels of FPI are associated with lower risk of incident AF in a middle-aged population with a long follow-up.

【 授权许可】

   
2014 Johnson et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG: Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009, 119(4):606-618.
• [2]Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271(11):840-844.
• [3]Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O: Atrial fibrillation in the Malmo Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 2010, 25(2):95-102.
• [4]Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A: Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011, 123(14):1501-1508.
• [5]Huxley RR, Filion KB, Konety S, Alonso A: Meta-analysis of cohort and case–control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011, 108(1):56-62.
• [6]Huxley RR, Alonso A, Lopez FL, Filion KB, Agarwal SK, Loehr LR, Soliman EZ, Pankow JS, Selvin E: Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 2012, 98(2):133-138.
• [7]Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, Page RL, Heckbert SR: Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010, 25(8):853-858.
• [8]Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R: Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 2009, 32(2):361-366.
• [9]Nilsson P, Nilsson JA, Hedblad B, Eriksson KF, Berglund G: Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmo Preventive Project. J Intern Med 2003, 253(2):136-145.
• [10]Fontes JD, Lyass A, Massaro JM, Rienstra M, Dallmeier D, Schnabel RB, Wang TJ, Vasan RS, Lubitz SA, Magnani JW, Levy D, Ellinor PT, Fox CS, Benjamin EJ: Insulin resistance and atrial fibrillation (from the Framingham Heart Study). Am J Cardiol 2012, 109(1):87-90.
• [11]Vyssoulis G, Karpanou E, Adamopoulos D, Kyvelou SM, Tzamou V, Michaelidis A, Stefanadis C: Metabolic syndrome and atrial fibrillation in patients with essential hypertension. Nutr Metab Cardiovasc Dis 2013, 23(2):109-114.
• [12]Tanner RM, Baber U, Carson AP, Voeks J, Brown TM, Soliman EZ, Howard VJ, Muntner P: Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol 2011, 108(2):227-232.
• [13]Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y: Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008, 117(10):1255-1260.
• [14]Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A: Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2010, 159(5):850-856.
• [15]Tang RB, Gao LY, Dong JZ, Liu XH, Liu XP, Wu JH, Long DY, Yu RH, Du X, Ma CS: Metabolic syndrome in patients with atrial fibrillation in the absence of structural heart disease from a tertiary hospital in China. Chin Med J (Engl) 2009, 122(22):2744-2747.
• [16]Barrett EJ, Liu Z: The endothelial cell: an “early responder” in the development of insulin resistance. Rev Endocr Metab Disord 2013, 14(1):21-27.
• [17]Baron AD: Hemodynamic actions of insulin. Am J Physiol 1994, 267(2 Pt 1):E187-E202.
• [18]Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94(446):496-509.
• [19]Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H, Lindgarde F: Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. J Intern Med 2000, 247(1):19-29.
• [20]Nilsson PM, Nilsson JA, Berglund G: Population-attributable risk of coronary heart disease risk factors during long-term follow-up: the Malmo Preventive Project. J Intern Med 2006, 260(2):134-141.
• [21]Heding L: A Simplified insulin radioimmunoassay method. J Labelled Comp 1965, 1(4):323.
• [22]Kristenson H, Trell E: Indicators of alcohol consumption: comparisons between a questionnaire (Mm-MAST), interviews and serum gamma-glutamyl transferase (GGT) in a health survey of middle-aged males. Br J Addict 1982, 77(3):297-304.
• [23]Waldo AL: Inter-relationships between atrial flutter and atrial fibrillation. Pacing Clin Electrophysiol 2003, 26(7 Pt 2):1583-1596.
• [24]Knuiman M, Briffa T, Divitini M, Chew D, Eikelboom J, McQuillan B, Hung J: A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol 2014, 29(3):181-190.
• [25]Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC: Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. Am Heart J 2008, 156(6):1163-1169.
• [26]Rosenberg MA, Patton KK, Sotoodehnia N, Karas MG, Kizer JR, Zimetbaum PJ, Chang JD, Siscovick D, Gottdiener JS, Kronmal RA, Heckbert SR, Mukamal KJ: The impact of height on the risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J 2012, 33(21):2709-2717.
• [27]Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87(6):2246-2252.
• [28]Baron AD, Brechtel-Hook G, Johnson A, Hardin D: Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993, 21(2):129-135.
• [29]Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, Panza JA: Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999, 100(8):820-825.
• [30]Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994, 94(6):2511-2515.
• [31]Defronzo RA, Mehta RJ, Schnure JJ: Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract (1995) 2013, 41(2):132-147.
• [32]Sinagra T, Tamburella A, Urso V, Siarkos I, Drago F, Bucolo C, Salomone S: Reversible inhibition of vasoconstriction by thiazolidinediones related to PI3K/Akt inhibition in vascular smooth muscle cells. Biochem Pharmacol 2013, 85(4):551-559.
• [33]Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Investig 1999, 104(4):447-457.
• [34]Muniyappa R, Sowers JR: Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013, 14(1):5-12.
• [35]Grundvold I, Skretteberg PT, Liestol K, Erikssen G, Kjeldsen SE, Arnesen H, Erikssen J, Bodegard J: Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 2012, 59(2):198-204.
• [36]Verdecchia P, Mazzotta G, Angeli F, Reboldi G: Above which blood pressure level does the risk of atrial fibrillation increase? Hypertension 2012, 59(2):184-185.
• [37]Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG, D'Agostino RB Sr, Kannel WB, Levy D, Benjamin EJ: Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007, 297(7):709-715.
• [38]Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Dahlof B, Kjeldsen SE, Wachtell K: Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension 2012, 60(2):347-353.
• [39]Bonnet F, Roussel R, Natali A, Cauchi S, Petrie J, Laville M, Yengo L, Froguel P, Lange C, Lantieri O, Marre M, Balkau B, Desir FE, Groups RS: Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts. Diabetologia 2013, 56(11):2414-2423.